Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US_Kintor Pharmaceutical Limited
    Research/Science 10/27/2022

    Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
    View this post in the Community →

    Similar Community Posts Join

    5 / 388 results

    Related Research

    6 / 1000+ results